SOUTH
SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 9, 2024
/PRNewswire/ -- Calico Life Sciences LLC (Calico) and the Broad
Institute of MIT and Harvard, announced today that the two organizations
have further extended their partnership with an added focus on
age-related neurodegeneration. Initially announced in March 2015, this renewed agreement extends the
collaboration until September 2029
and will continue to support ongoing programs focused on the
biology and genetics of aging as well as early-stage drug
discovery. Terms of the agreement were not disclosed.
"We are pleased to continue our collaboration with the Broad
Institute. It is entering its tenth year and we've made a
considerable amount of progress, including discoveries that could
make immunotherapies more effective for more patients. We are
currently testing this approach in two early-stage clinical trials
evaluating a pair of PTPN2 inhibitors," said Arthur D. Levinson, Ph.D., Founder and CEO of
Calico. "With the expansion of our partnership to include
age-related neurodegeneration, we are tackling a critical area of
discovery that will allow us to access our collective expertise to
advance an important area of research and clinical
development."
"Renewing our commitment to this partnership with Calico
reflects our shared goal of advancing transformative biomedical
research and therapies for age-related diseases," said Todd Golub, M.D., Director and founding core
member of the Broad Institute. "Since we initiated our partnership,
we have seen tremendous advances across new technologies and
analytic methods that are enabling the discovery of new biological
insights into human disease that have immediate impact on drug
discovery. We look forward to working with the Calico team to
further our insights into how aging impacts the brain and
neurological function."
About Calico
Calico (Calico Life Sciences LLC) is an
Alphabet-founded research and development company whose mission is
to harness advanced technologies to increase our understanding of
the biology that controls lifespan. Calico will use that knowledge
to devise interventions that enable people to lead longer and
healthier lives. To learn more about Calico, visit
www.calicolabs.com.
About Broad Institute of MIT and
Harvard
Broad Institute of
MIT and Harvard was launched in 2004 to empower this
generation of creative scientists to transform medicine. The Broad
Institute seeks to describe the molecular components of life and
their connections; discover the molecular basis of major human
diseases; develop effective new approaches to diagnostics and
therapeutics; and disseminate discoveries, tools, methods and data
openly to the entire scientific community.
Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary
Los Angeles philanthropists
Eli and Edythe L. Broad, the Broad
Institute includes faculty, professional staff and students from
throughout the MIT and Harvard biomedical research communities and beyond,
with collaborations spanning over a hundred private and public
institutions in more than 40 countries worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calico-and-broad-institute-extend-collaboration-adding-focus-on-age-related-neurodegeneration-302140620.html
SOURCE Calico Life Sciences LLC